Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity was posted on March 8, 2019. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

DRAFT RFP - Biological Specimen and Investigational Product (CSN BSIP) Storage Facility

Closed
19-BARDA-DRAFT-CSN-BSIPFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
AJ12--Development/Production - Kidney GEC-Specific AAV Vector
Solicitation # 36C24E27Q0009
The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.
Rpo East (36C24E)

POSTED

about 11 hours ago

DEADLINE

in 14 days
NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 3 months
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 3 months

General Info

Agency

N/A

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

2 updates
PhaseClosed
Posted

special-notice

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Enrique MananContracting Officer

Full Description

Show more
Note: This is only a brief introduction. Please read the entire DRAFT RFP to ensure you have a clear understanding of the Government's intended requirement. March 6, 2019 Dear Ladies and Gentlemen: The Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) is requesting feedback (questions and comments) from Contract Research Organizations (CRO) and other similar entities who work in the Clinical Study area regarding the following three (3) BARDA DRAFT RFPs: 1. 19-BARDA-DRAFT-CSN-BSIP 2. 19-BARDA-DRAFT-CSN-SDCC 3. 19-BARDA-DRAFT-CSN-CTPE Combined, these three (3) DRAFT RFPs will form the revised Clinical Studies Network (CSN) Contract Research Organizations (CROs) for CBRNE Medical Countermeasures (MCMs). Specifically, BARDA is seeking feedback form those interested entities involved in Clinical Trial Planning and Execution, Statistical and Data Coordinating Center activities, and Biological Specimen and Investigational Product Storage. Questions and comments should be submitted by Close of Business (COB) on March 12, 2019 as outlined below, in preparation for a pre-proposal conference (see below for details). Feedback from all capable and qualified sources would be appreciated. The following are notices relating to this request for feedback: - Feedback from prospective Responders will not provide them with an advantage nor disadvantage in future solicitations. - All Feedback will be reviewed and responses to feedback and questions will be posted on the Federal Business Opportunities Website (www.fedbizopps.gov). - No company information will be revealed to the public to include which companies asked particular questions. - The posting of information about this requirement does not express or imply any commitment by the Government to issue a final RFP or the promise for any contract action. - Any information and notices concerning the release of a final RFP will be posted on the Federal Business Opportunities Website (www.fedbizopps.gov) when available. FORMAT Responses shall adhere to the following formatting and outline instructions: 1. Format specifications include 8.5 by 11 inch paper. All submissions must be in a format compatible with the Microsoft Office or Adobe software package and electronically submitted as follows: To: enrique.manan@hhs.gov Cc: marcy.grace@hhs.gov 2. Cover Page (1 page) a. Title b. Organization c. Respondents' technical and administrative points of contact (names, addresses, phones and fax numbers, and email addresses) d. Respondents' intent to participate either in person or via teleconference at the below identified pre-proposal conference. 3. Feedback to Draft RFP (19-BARDA-DRAFT-CSN-BSIP) (no page limit) a. Questions should be numbered with at least one line space between each question. b. Please identify the DRAFT RFP No. and the RFP Section for each question. The posting of information about this requirement does not express or imply any commitment by the Government to issue a final RFP or the promise for any contract action. The point(s) of contact for this DRAFT RFP are as follows: Enrique Man: enrique.manan@hhs.gov Marcy Grace: marcy.grace@hhs.gov BARDA encourages open communication from all potential Responders. A combined conference call (with all interested potential Responders) to discuss this DRAFT RFP has been scheduled as follows: DATE: Friday, March 22, 2019 *DATE UPDATED* TIME: TBD LOCATION: Conference Call / Washington, DC CALL IN INFO: TBD Thank you for your interest in doing business with the Federal Government.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS